BTIG analyst Julian Harrison lowered the firm’s price target on Rezolute (RZLT) to $5 from $17 and keeps a Buy rating on the shares. The firm “conservatively” removed ersodetug in congenital hyperinsulinism from Rezolute’s model following the Phase 3 failure. BTIG also reduced ersodetug in tumor hyperinsulinism’s probability of success to 65% from 70%.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RZLT:
- Rezolute downgraded to Market Perform from Outperform at Citizens
- Rezolute downgraded to Neutral from Overweight at Cantor Fitzgerald
- Wedbush downgrades Rezolute to Neutral after congenital hyperinsulinism miss
- Rezolute Downgraded to Hold Amid Disappointing Phase 3 Trial Results for Ersodetug
- Rezolute downgraded to Neutral from Outperform at Wedbush